DGAT1 and obesity due to melanocortin 4 receptor deficiency: Since there is a report that Compound A shows beneficial metabolic effects [10], we focused on whether the predominantly intestine-targeted DGAT1 inhibitor could improve obesity and insulin resistance without skin aberrations in mice in the present study.